Related by context. All words. (Click for frequent words.) 86 Secondary endpoints include 76 Secondary endpoints 73 Primary endpoints 71 progression TTP 70 ADCS CGIC 70 demonstrated clinically meaningful 69 secondary endpoint 68 Montgomery Asberg Depression 68 WOMAC pain 68 Secondary efficacy endpoints 68 prespecified secondary 67 secondary efficacy endpoint 67 Tasigna prolongs 66 morphometric vertebral fractures 66 4mg/kg 66 nasal symptom 66 P = .# 66 tumor progression TTP 66 achieved statistical significance 66 Brief Psychiatric 66 confirmed CCyR 66 prednisone prednisolone plus 66 -#.# mg dL [001] 66 mcg QD 66 secondary endpoints 66 CIMZIA TM certolizumab pegol 66 adjuvant GIST 66 GERD symptom 65 CI -#.# 65 #.#/#.# mmHg [001] 65 8mg/kg 65 ADAS Cog 65 postintervention 65 p = #.# [004] 65 ischemia driven 65 placebo p = 65 mg QD 65 secondary efficacy endpoints 65 radiotherapy RT 65 Crohn Disease Activity 65 demonstrated statistically significant 65 hematological parameters 65 primary efficacy endpoint 65 elevated transaminases 65 biochemical relapse 65 CRp 65 postoperative AF 65 serum phosphorous 65 CCyR 65 desvenlafaxine succinate 65 IRLS 65 Pharmacokinetics PK 65 achieved ACR# 65 prospectively defined 64 posttreatment 64 endoscopic remission 64 Index CDAI 64 % Confidence Interval 64 ACTEMRA TM 64 Median progression 64 melphalan prednisone 64 recovery CRp 64 glycosylated hemoglobin levels 64 prospectively stratified 64 ADAS cog 64 Alzheimer Disease Assessment 64 Erythropoietic therapies may 64 headache nasopharyngitis 64 methacholine challenge 64 International Prostate Symptom 64 pharmacodynamic PD 64 biochemical recurrence 64 Scale EDSS 64 patients evaluable 64 intravascular hemolysis 64 p = #.# [002] 64 Rating Scale MADRS 64 abacavir lamivudine 64 oxycodone CR 64 Key secondary endpoints 64 HAQ DI 64 colorectal adenoma 64 Free Survival PFS 64 CDAI 64 FOLFIRI alone 64 Zometa hazard 64 p = NS 64 nonfatal myocardial infarction 64 Efficacy endpoints 64 certolizumab 64 abdominal pain abdominal discomfort 64 -#.# ± [002] 63 partial remissions 63 evaluable 63 calculated creatinine clearance 63 HBeAg negative patients 63 % CI #.#-#.# [003] 63 PCWP 63 liver histology 63 chemoradiation therapy 63 hemodynamic measurements 63 QTcF 63 Kaplan Meier estimates 63 Visual Analogue Scale VAS 63 placebo p 63 CR CRu 63 metastatic pancreatic 63 NMIBC 63 unresectable HCC 63 aspartate aminotransferase AST 63 Negative Syndrome 63 PANSS total 63 zonisamide SR 63 Montgomery Åsberg Depression 63 pharmacokinetics PK 63 ATACAND 63 reinfarction 63 Events MACE 63 mg TID 63 RECIST Response Evaluation Criteria 63 YMRS 63 deep venous thromboses 63 posttransplant 63 FUSILEV enhances 63 HOMA IR 63 neurologic progression 63 PSA nadir 63 LDL triglycerides 63 lispro 63 microbiologically evaluable 63 haematologic 63 locoregional recurrence 63 #mg/day [002] 63 glycoprotein IIb IIIa inhibitor 63 serologically active patients 63 PANSS 63 #mg/day [001] 63 NIH CPSI 63 recurrent glioblastoma multiforme 63 ACR# ACR# 63 undetectable HBV DNA 63 oral rivaroxaban 63 ALT normalization 63 Flu Cy 63 TURBT 63 Psoriasis Area 63 -#.# mg dL [002] 63 Prognostic significance 63 confidence interval CI 63 WOMAC TM 63 primary endpoint 63 tipranavir r 62 CIMZIA TM 62 prespecified 62 nicardipine 62 multivariate Cox 62 reactogenicity 62 clinicopathological features 62 DLQI 62 histologic 62 BEXXAR Therapeutic Regimen 62 bronchial hyperresponsiveness 62 -#.# log# copies mL 62 serum aminotransferase levels 62 tumor histology 62 timepoints 62 μg kg 62 plus octreotide LAR 62 HDRS 62 preoperative PSA 62 HES CEL 62 #mg BID [003] 62 achieved PASI 62 pharmacokinetic parameters 62 postoperative complication 62 urine albumin 62 left ventricular diastolic 62 activated partial thromboplastin 62 confidence interval #.#-#.# 62 HF hospitalization 62 SGRQ 62 mesalamine granules 62 Scale PANSS 62 relapsed MM 62 adenoma recurrence 62 Mean Symptom Complex 62 adjuvant cisplatin 62 symptomatic VTE 62 Severity MSCS score 62 #mg QD [002] 62 pharmacodynamics PD 62 bortezomib refractory 62 mcg BID 62 statistically significant improvement 62 genotypic resistance 62 Global Impression 62 myelodysplastic myeloproliferative diseases 62 oral antidiabetic medication 62 IIIa inhibitor 62 intact parathyroid hormone 62 serum urate 62 â ‰ ¥ 62 NYHA functional class 62 BENICAR HCT 62 cytogenetic response 62 response CCyR 62 corticosteroid dose 62 PASI scores 62 Postoperative 62 mg qd 62 malignancy HCM 62 Score DAS# 62 Inventory BPI 62 composite endpoint 62 fasting plasma glucose FPG 62 mild hepatic impairment 62 IBDQ 62 p = .# [002] 62 Cystic Fibrosis Questionnaire Revised 62 hemoglobin A1c HbA1c 62 tirofiban 62 spontaneous bowel movements 62 EBMT criteria 61 lipid parameters 61 microbiological eradication 61 glycosylated hemoglobin HbA1c 61 fractional shortening 61 Fibromyalgia Impact Questionnaire 61 HBeAg positive patients 61 mediated dilation 61 attain statistical significance 61 Global Impression CGI 61 stage IIIb IV 61 clinically meaningful improvements 61 MADRS 61 binary restenosis 61 Neuropsychiatric Inventory NPI 61 DAS# CRP 61 CI #.#-#.# [002] 61 NSAID associated 61 CYP#D# inhibitor 61 cisplatin gemcitabine 61 overt nephropathy 61 MDS MPD 61 TAXUS p value 61 primary percutaneous coronary 61 metabolic parameters 61 Severity Index PASI 61 death reinfarction 61 linaclotide treated 61 demonstrated antitumor activity 61 = #.#-#.# 61 urinary N telopeptide 61 ACR Pedi 61 % CI #.#-#.# [007] 61 lowest tertile 61 cEVR 61 FOLFOX4 61 recurrent ischemia 61 cytogenic 61 permanently discontinue Vectibix 61 catheter occlusion 61 irbesartan 61 pain palliation 61 moderate renal impairment 61 NIHSS 61 vitreous floaters 61 limiting toxicity DLT 61 Score TOS 61 chlorambucil 61 XIENCE V PROMUS Stent 61 debulking surgery 61 PROCTOCORT ® Suppository Hydrocortisone 61 lumbar spine BMD 61 hip BMD 61 mitoxantrone plus 61 ug kg 61 UPDRS motor 61 CorVue ™ 61 TO AVOID PREGNANCY WHILE 61 ratio ICER 61 angiographic restenosis 61 clinically meaningful improvement 61 patients undergoing CABG 61 Known hypersensitivity 61 ADCS ADL 61 Qmax 61 aPTT 61 systolic function 61 MADRS score 61 Prostate specific antigen 61 receiving XGEVA 61 rosuvastatin #mg 61 creatinine ratio 61 HAM D# 61 tolterodine ER 61 Kaplan Meier method 61 clinically meaningful reductions 61 phonophobia 61 budesonide pMDI 61 plus methotrexate 61 nonfatal myocardial infarction MI 61 epoetin alpha 61 mucosal healing 61 unfractionated heparin UFH 61 NNT = 61 Insulin sensitizers 61 Main Outcome Measures 61 nonfatal MI 61 BENICAR 61 6MWD 61 venous thromboembolic disease 61 XIENCE V demonstrated 61 postop 61 p = 61 IPSS 61 plus prednisone 61 Solid Tumors criteria 61 CR nPR 61 achieved CCyR 61 brachial artery flow 61 fructosamine 61 HAMD 61 annualized relapse 61 histological subtype 61 docetaxel pretreated 61 myocardial infarction ventricular fibrillation 61 symptom exacerbation 61 galiximab 61 ispinesib administered 61 PLX STROKE targeting 60 BPH symptom 60 Negative Symptoms 60 SSRI SNRI 60 events MACE 60 Visual Analog Scale 60 CFQ R 60 #mg/m# [001] 60 glycated hemoglobin levels 60 tumor lysis syndrome 60 Thrombolysis 60 HER2 expression 60 CDAI score 60 subscales 60 QTc 60 mg BID 60 serum cortisol 60 Folfox 60 Fasting plasma glucose 60 HbA1C levels 60 diarrhea dyspepsia 60 PSADT 60 papillary renal cell carcinoma 60 Acetate Rectal Suppositories 60 obstructive CAD 60 nasopharyngitis headache 60 graft dysfunction 60 #mg/m# [002] 60 Kaplan Meier analysis 60 HBeAg seroconversion 60 Pharmacodynamic 60 plus prednisone prednisolone 60 achieve sustained virologic 60 recurrent venous thromboembolism 60 severe oral mucositis 60 lumen diameter 60 severe exacerbations 60 TNF Tumor Necrosis Factor 60 Pharmacokinetic parameters 60 Major Adverse Cardiac 60 LANTUS R 60 postoperative radiotherapy 60 -#.# log# 60 metastatic GIST 60 coronary stenosis 60 CIMZIA ™ 60 Tumor Response 60 nausea photophobia 60 pretransplant 60 Main Outcome Measure 60 erythrocyte sedimentation rate 60 FOLFOX6 60 tapentadol ER 60 exploratory endpoints 60 mg ustekinumab 60 #μg [002] 60 seminal vesicle invasion 60 repeat paracentesis 60 echocardiographic parameters 60 inhaled iloprost 60 BMI z 60 response pCR 60 postdose 60 PSA kinetics 60 KRAS mutant tumors 60 gadolinium enhancing lesions 60 ACR# response 60 nonsignificant 60 non splenectomized 60 QIDS SR 60 RECIST criteria 60 diameter stenosis 60 primary endpoints 60 urate lowering 60 esophageal carcinoma 60 DAS# remission 60 Score DAS 60 Unified Parkinson Disease 60 estimated glomerular filtration 60 fatigue abdominal pain 60 pT3 60 symptomatic intracranial hemorrhage 60 cough dyspnea 60 tissue oxygenation 60 dyspnoea 60 advanced hepatocellular carcinoma 60 thromboembolic events 60 pCR 60 relapsed MCL 60 histologic subtype 60 alanine aminotransferase ALT 60 methotrexate monotherapy 60 oral levofloxacin 60 irinotecan cisplatin 60 plasma leptin 60 hyperphenylalaninemia HPA due 60 remission CR 60 postprocedure 60 esophagogastric 60 Cypher Stent 60 Postoperatively 60 arterial oxygen saturation 60 periprocedural 60 hepatic enzyme 60 metastatic malignant 60 moderate hepatic impairment 60 apolipoprotein B 60 Clinically significant 60 neurocognitive function 60 β blocker 60 p = #.# [003] 60 locoregional control 60 intravenous bolus 60 CSBM 60 mg p = 60 aspirin clopidogrel 60 infliximab monotherapy 60 aplastic anemia AA 60 LV ejection fraction 60 plus MTX 60 pmol L 60 atheroma volume 60 myocardial reperfusion 60 estramustine 60 perioperative complications 60 hepatic function 60 Seattle Angina Questionnaire 60 free survival PFS 60 glycoprotein IIb IIIa inhibitors 60 SpO2 pulse rate 59 postoperative morbidity 59 F FDG PET 59 sUA 59 VELCADE melphalan 59 nonhematologic adverse reactions 59 APTIVUS r 59 intratumoral 59 GI motility 59 saline placebo 59 atorvastatin #mg 59 primidone 59 hemodynamic parameters 59 serum HBV DNA 59 SBM frequency 59 FluCAM arm 59 Response Evaluation Criteria 59 TAXUS Express Stent 59 Scale cognitive subscale 59 fluticasone salmeterol 59 albumin excretion rate 59 antiarrhythmic drug 59 confidence intervals CIs 59 pretreatment serum 59 timepoint 59 hemodynamic variables 59 multivariable Cox 59 alanine aminotransferase 59 methemoglobin SpMet 59 highest tertile 59 Health Assessment Questionnaire 59 Persistent Sleep 59 ropivacaine 59 sumatriptan naproxen sodium 59 intraobserver 59 alfuzosin 59 scintigraphic 59 EQ 5D 59 statistically significant p 59 Q#IR 59 lispro alone 59 ≥ 59 Index CDAI score 59 XIENCE V vs. 59 fibrinolytic therapy 59 eptifibatide 59 trough FEV1 59 walk distance 6MWD 59 neutropenic sepsis 59 fluoropyrimidine 59 Radical prostatectomy 59 tolerability profiles 59 receiving VELCADE 59 univariate 59 QTc intervals 59 tertile 59 complete cytogenetic 59 lopinavir r arm 59 hematologic parameters 59 atrioventricular block 59 stent binary restenosis 59 Annualized Relapse Rate ARR 59 NSTE ACS 59 chronic thromboembolic pulmonary 59 SCr 59 SVR# 59 bypass graft CABG surgery 59 hemorrhagic complications 59 Partial Response 59 UPDRS 59 tamoxifen Nolvadex ® 59 achieved sustained virologic 59 MACCE 59 preoperative chemotherapy 59 Viral load 59 + PH# 59 pulmonary exacerbations 59 somatostatin analog 59 subjective sleepiness 59 Hazard Ratio HR 59 ug dose 59 antiretroviral naïve 59 doxorubicin cyclophosphamide 59 CYP#A# substrate 59 intima media thickness 59 % CI #.#-#.# [006] 59 UACR 59 LEXIVA r 59 Kaplan Meier 59 metastatic colorectal carcinoma 59 hemoglobin Hb 59 intima media thickness IMT 59 unresectable tumors 59 Score IPSS 59 crizotinib PF # 59 lactate dehydrogenase 59 Target Lesion Revascularization TLR 59 indicates cardio circulatory 59 nadroparin 59 systemic hypotension 59 cyclophosphamide vincristine 59 pharmacokinetic PK 59 IV bolus 59 pegylated interferon peg IFN 59 triiodothyronine 59 surrogate endpoint 59 peginterferon alfa 2a #KD 59 pericardial effusion 59 β blockers 59 graft occlusion 59 univariate analysis 59 complete cytogenetic response 59 Platinol ® cisplatin 59 CNS LS 59 paricalcitol 59 atazanavir ritonavir 59 neutropaenia 59 elevated ALT 59 Y BOCS 59 AUA Symptom Score 59 statistically significant p = 59 SIMPADICO 59 ritonavir boosted 59 EGFr expressing metastatic colorectal 59 EDARBI 59 natriuresis 59 pharmacokinetic PK profile 59 refractory ischemia 59 Preoperative 59 cystoscopic 59 p = .# [001] 59 locoregional 59 bone marrow reticulin deposition 59 pulmonary capillary wedge 59 glomerular filtration 59 reduce serum phosphate 59 quetiapine XR 59 -#.# mm Hg 59 clevidipine 59 CrCl 59 vasomotor 59 mL/min/#.# m2 59 hepatocellular 59 mitoxantrone 59 clinically evaluable population 59 fasting insulin 59 angioplasty stenting 59 intracoronary 59 Improved Progression 59 diarrhea abdominal 59 thrombocytopenic 59 Long Term Efficacy 59 extrapyramidal side 59 Rating Scale UPDRS 59 serum leptin 59 octreotide LAR 59 administered cetrorelix 59 Sustained virologic response 59 CTEPH 59 liver transaminases 59 concomitant medications 59 intermittent dosing 59 elevated creatinine 59 #.#mmHg 59 TEAEs 59 transthoracic 59 coronary revascularization 59 mL/min/#.# m 2 59 CYP#A# CYP#D# 59 LVSD 59 salmeterol fluticasone 58 AST ALT 58 endometrial thickness 58 specific alkaline phosphatase 58 mTSS 58 postoperative chemotherapy 58 paclitaxel cisplatin 58 elevated IOP 58 underwent resection 58 inotropic 58 Cmax 58 underwent surgical resection 58 Patients Receiving 58 concurrent chemoradiation 58 MGN# 58 plasma creatinine 58 microsomal 58 dose cohort 58 Ishak fibrosis score 58 PANSS scores 58 left ventricular LV 58 FDG-PET/CT 58 Status Scale EDSS 58 Pain Intensity 58 CANCIDAS 58 subscores 58 electrophysiologic 58 Pharmacokinetic 58 incidence ≥ 58 overt hepatic encephalopathy HE 58 lactate dehydrogenase LDH 58 coronary revascularisation 58 multivariate adjustment 58 R# #mg BID 58 ARB telmisartan 58 warfarin erythromycin 58 LV dysfunction 58 aspartate aminotransferase 58 FEV1 forced expiratory 58 Insulin PH# 58 pharmacokinetic profiles 58 specific antigen PSA 58 Hamilton Rating Scale 58 TLUS 58 renal cysts 58 mg BID dose 58 abdominal computed tomography 58 achieving hemostasis 58 insulin detemir 58 shortens systolic ejection 58 ionotropic 58 QTc prolongation 58 mcg kg 58 pyrimidine nucleoside analog 58 otamixaban 58 Thrombotic thromboembolic complications 58 pegylated interferon alfa 2b 58 oocytes retrieved 58 splenectomized 58 coadministration 58 C telopeptide 58 urinary albumin 58 SELENA SLEDAI 58 dosage regimens 58 Kaplan Meier survival 58 nonalcoholic steatohepatitis NASH 58 Univariate analysis 58 preintervention 58 transrectal ultrasound guided 58 GAMMAGARD 58 hypereosinophilic syndrome 58 Histologic 58 adjunctive placebo 58 nucleoside naive 58 VcMP 58 Zemplar Capsules 58 nondiabetic patients 58 KRAS mutations occur 58 Cimzia TM 58 CINQUIL 58 carotid intima media 58 preoperatively 58 DAS# scores 58 fasting plasma glucose 58 1mg dose 58 dosing cohort 58 serum potassium 58 Coronary artery bypass grafting 58 affective psychosis 58 non valvular atrial 58 EMBLEM TM 58 naïve HCV 58 GOUT 58 ventilatory 58 subscale scores 58 bolus dose 58 antidiabetic medications 58 completely resected 58 FOLFOX4 alone 58 ULORIC 58 fibrinolysis 58 oral anticoagulant therapy 58 Cardiopulmonary bypass 58 plasma triglycerides 58 nadolol 58 Neuropsychiatric Inventory 58 RoACTEMRA 58 x ULN 58 chronic hemodialysis 58 selective modulator 58 brand ciclesonide HFA 58 SSRI citalopram 58 Hazard Ratio 58 CC genotype 58 comparator arm 58 Operative mortality 58 QRS duration 58 caspofungin 58 axillary lymph node 58 distant metastasis 58 Apolipoprotein B 58 q#h 58 meta regression 58 systemic corticosteroid 58 postprandial blood glucose 58 MoxDuo TM IR 58 % CI #.#-#.# [008] 58 CI #.#-#.# [001] 58 liver metastasis 58 opioid naïve 58 virological response 58 PEG IFN 58 eplerenone 58 mg kg BID 58 antiarrhythmic medications 58 PEGylated anti 58 pyrexia mucositis sepsis febrile 58 teriflunomide 58 ADHD Rating Scale 58 #mg QD [001] 58 peak VO2 58 CK # administered 58 NSTEMI 58 plus gemcitabine 58 placebo PBO 58 EDEMA3 trial 58 MCyR 58 oblimersen 58 retinal thickness 58 receiving prophylactic anticoagulation 58 cerebrovascular events 58 transcranial Doppler ultrasound 58 INTEGRILIN R eptifibatide Injection 58 transabdominal 58 quantitative coronary angiography 58 STRIDE PD 58 AUC0 58 iPTH 58 tumor resection 58 3mg/kg 58 Cystatin C 58 RRM1 58 lymphovascular invasion 58 Lupuzor ™ 58 bioprosthetic valve 58 mRS 58 CYT# potent vascular disrupting 58 5 Fluorouracil 58 IFN alfa 58 infusional 58 CLL SLL 58 Demonstrated Significant 58 cardiovascular calcification 58 postoperative mortality 58 UPDRS Part III 58 HBeAg 58 Disease Activity 58 humanized interleukin 6 58 lymphocytosis 58 PANSS Positive 58 HbA 1c 58 Natalizumab 58 weekly subcutaneous injections 58 % CI #.#-#.# [001] 58 Thal Dex 58 piperacillin tazobactam 58 TIMP 1 58 receiving highly emetogenic 58 5 FU leucovorin 58 Carotid endarterectomy 58 fluticasone propionate FP 58 neutropenia dehydration dyspnea 58 Brief Pain 58 #.#mg/dL 58 AGILECT R 58 vapreotide acetate 58 SGPT 58 heparin induced thrombocytopenia 58 Solid Tumors RECIST 58 recurrent DVT 58 R Saizen R 58 pulmonary artery banding 58 intravesical therapy 58 International Normalized Ratio 58 interferon ribavirin 58 Mg Usa 58 chills fever headache 58 polycythemia vera essential thrombocythemia 58 carotid endarterectomy CEA 58 n = 58 plus medroxyprogesterone acetate 58 REMINYL ® 58 mild renal insufficiency 58 drotrecogin alfa activated 58 corrected QT interval 58 T2 lesion volume 58 BARACLUDE r 58 #mg BID [001] 58 nonvertebral fracture 58 symptom severity 58 Pfizer respectfully disagrees 58 ribavirin RBV 58 hemodilution 58 leukocyte count 58 unfavorable cytogenetics 58 leucopenia 58 prospectively evaluated 58 Vidaza ® 58 Hb A1C 58 oral prednisolone 58 chronic idiopathic thrombocytopenic purpura 58 IL#B 58 refractory chronic lymphocytic 57 biliary tract cancer 57 pharmacodynamic parameters 57 HbA 1c levels 57 non squamous histology 57 ALVESCO 57 hemodialysis patients 57 primary efficacy endpoints 57 pruritus itching 57 -#.# ± [001] 57 Dyspnea 57 NPH insulin 57 sustained virological response 57 receiving INTRON 57 virologic breakthrough 57 endothelin antagonists 57 serum triglycerides 57 ANCOVA 57 Efficacy Results 57 Left Ventricular Ejection Fraction 57 Cardiac Resynchronization 57 acromegalic patients 57 urothelial carcinoma 57 hepatorenal syndrome 57 sensitivity specificity 57 refractory NSCLC 57 N telopeptide 57 achieving PASI 57 patients coinfected 57 linoleic acid LA 57 hormone receptor negative 57 everolimus eluting stents 57 pulmonary vascular 57 myelosuppressive 57 mmHg diastolic 57 acutely decompensated congestive heart 57 esophageal gastric 57 autoantibody levels 57 baseline LDH 57 mL kg 57 left ventricular systolic 57 nab paclitaxel 57 CTNNB1 57 concurrent ITP 57 log# IU mL 57 EORTC QLQ C# 57 tolerability pharmacokinetics 57 receiving golimumab 57 ARCOXIA 57 ^ Tc 57 Acute Coronary Syndromes ACS 57 oral FTY# 57 ventricular tachyarrhythmia 57 salmeterol fluticasone propionate 57 detectable HCV RNA 57 semiquantitative 57 eNO 57 multivariable adjusted 57 Ceplene/IL-2 57 nighttime awakenings 57 posttest 57 lumbar spine bone 57 oral anticoagulation 57 #.#ng/ml 57 analgesic efficacy 57 dose escalation phase 57 plus dexamethasone 57 induce remission 57 coagulation parameters 57 rFSH 57 CT perfusion 57 ß blockers 57 sunitinib Sutent 57 NOXAFIL Oral Suspension 57 Intravitreal 57 Naive Patients 57 liposomal doxorubicin 57 histologically confirmed 57 Xalatan R 57 CIMZIA R 57 prospective multicentre 57 ipsilateral breast 57 antiangiogenic agent 57 microgram kg 57 fosbretabulin 57 5-fluorouracil/leucovorin 57 GLIADEL R Wafer 57 -#.# mmHg 57 events thrombocytopenia neutropenia 57 electrical cardioversion 57 chemoradiotherapy 57 nucleoside naive patients 57 WOMAC 57 urothelial 57 plasma lipids 57 sirolimus eluting stents 57 Castration Resistant Prostate Cancer 57 hemostatic efficacy 57 extrapyramidal symptoms 57 angiographic outcomes 57 lipid lowering agents 57 perioperatively 57 serum phosphate 57 mCi kg 57 REYATAZ r arm 57 EXJADE 57 bronchoalveolar lavage 57 receiving VICTRELIS 57 serum bicarbonate 57 nodular partial response 57 cells mcL 57 biphasic insulin aspart 57 conjunctival hyperemia 57 CORE OM 57 5-FU/LV 57 mU liter 57 mg subcutaneous 57 subcutaneous enoxaparin 57 spirometric 57 dalteparin 57 symptomatic intracerebral hemorrhage 57 mg/m2/day 57 dose dependently 57 hypoglycemic events 57 hepatic enzymes 57 radical prostatectomy RP 57 chronic eosinophilic leukemia 57 Prognostic factors 57 triglycerides LDL 57 baseline HbA1c 57 BUPHENYL R sodium phenylbutyrate 57 non menstrual pelvic 57 Mg Uk 57 torsade de pointes 57 lamotrigine 57 adefovir treated 57 resuscitated cardiac arrest 57 approved incretin mimetic